Karmanos Expands Radiopharmaceutical Therapies Across Michigan Network
Event summary
- Karmanos Cancer Institute is expanding access to radiopharmaceutical therapies (RPTs) – Lutathera, Pluvicto, and Xofigo – to its network locations in Michigan.
- Pluvicto and Xofigo are now available at Karmanos Cancer Institute at McLaren Macomb, while Pluvicto is available at Karmanos Cancer Institute at McLaren Greater Lansing.
- Karmanos has administered nearly 850 theranostic infusions to date and has invested in SPECT/CT imaging technology.
- The Institute has been a pioneer in radiopharmaceuticals since 2017, participating in clinical trials including one that led to FDA approval of Pluvicto.
The big picture
Karmanos' expansion reflects the growing adoption of theranostics in oncology, a field promising more targeted and less toxic cancer treatments. The move to broaden access across its network suggests a strategic focus on expanding market reach and solidifying its position as a leader in this specialized area. This expansion also highlights the increasing importance of partnerships with regional healthcare providers like McLaren to deliver advanced cancer care.
What we're watching
- Network Adoption
- The speed of adoption of these therapies across the broader Karmanos network will indicate the logistical and training challenges involved in scaling specialized treatments.
- Reimbursement
- Continued access to these therapies will depend on favorable reimbursement rates from both public and private payers, which could be impacted by cost and demonstrated efficacy.
- Competitive Landscape
- The emergence of competing radiopharmaceutical therapies and institutions offering similar services will likely intensify, requiring Karmanos to maintain a technological and clinical edge.
Related topics